Login to Your Account

ICAAC Roundup

Thursday, September 12, 2013
• Chimerix Inc., of Durham, N.C., disclosed results from its exploratory Phase II Study 202 evaluating brincidofovir (CMX001) in hematopoietic cell transplant (HCT) recipients with early adenovirus (AdV) infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription